Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)

被引：0
|
作者：
Bossi, P. [1 ]
Minuti, G. [2 ]
Brana, I. [3 ]
Garcia, V. Moreno [4 ]
Boni, V. [5 ]
Jamme, P. [6 ]
Call, J. A. [7 ]
Yan, C. [8 ]
Barasa, B. [9 ]
Doze, P. [10 ]
Joe, A. K. [11 ]
Laus, G. [11 ]
Daste, A. [12 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol, Milan, Italy
[2] IRCCS Ist Nazl Tumori Regina Elena IRE, Phase & Precis Med Unit 1, Rome, Italy
[3] Vall Hebron Univ Hosp, Thorac Canc Unit, Barcelona, Spain
[4] Hosp Univ Fdn Jimenez Diaz, START Madrid, FJD Early Phase Clin Trials Unit, Madrid, Spain
[5] Hosp Univ Quironsalud Madrid, Oncol Dept, Pozuelo De Alarcon, Spain
[6] CHU Lille, Haut France, Ctr Hosp Reg Univ Lille, Lille, France
[7] South Texas Accelerated Res Therapeut START, Phase & Trials, San Antonio, TX USA
[8] Merus NV, Biostat, Utrecht, Netherlands
[9] Merus NV, Translat Res, Utrecht, Netherlands
[10] Merus NV, Clin Operat, Utrecht, Netherlands
[11] Merus NV, Clin Dev, Utrecht, Netherlands
[12] CHU Bordeaux, Hop St Andre, Med Oncol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.470
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
362P
引用
收藏
页码：S1610 / S1611
页数：2
相关论文
共 50 条
  • [1] Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
    Geuijen, Cecile
    di Matteo, Mario
    Gallenne, Tristan
    Cafarello, Sarah Trusso
    Nijhuis, Roy
    Visser, Therese
    Bartelink, Willem
    Bartelink-Clements, Carina
    Eppink, Berina
    Klooster, Rinse
    Dekruif, John
    Mazzone, Massimiliano
    Throsby, Mark
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [2] Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)
    Wang, Jie
    Zhong, Jia
    Wu, Lin
    Chen, Bolin
    Wang, Zhe-Hai
    Yao, Yu
    Dong, Xiaorong
    Li, Wei
    Ren, Xiubao
    Hou, Xiaoming
    Zang, Ai-min
    Qu, Xiujuan
    Zhang, Guojun
    Wang, Yongsheng
    Bai, Yuansong
    Liu, Linlin
    Yu, Guohua
    Chen, Xingwu
    Ding, Lieming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
    Brandao, Mariana da Rocha Almeida
    Zugazagoitia, Jon
    Dingemans, Anne-Marie C.
    Duruisseaux, Michael
    Parent, Pauline
    Juan-Vidal, Oscar
    Spira, Alexander I.
    Vicier, Cecile
    Zalcman, Gerard
    Barasa, Ben
    Yan, Chris
    Doze, Petra
    Joe, Andrew K.
    Laus, Gianluca
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
    Cappuzzo, F.
    Moreno Garcia, V.
    Ou, S-H. I.
    Brandao, M.
    Sanmamed, M. F.
    Helissey, C.
    Wislez, M.
    Call, J. A.
    Grisanti, S.
    Johnson, M. L.
    Boni, V.
    Jamme, P.
    Monnet, I.
    Siena, S.
    Yan, C.
    Barasa, B.
    Richard, B.
    Joe, A. K.
    Laus, G.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1671 - S1671
  • [5] Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab
    de Gorter, David J. J.
    Deshiere, Alexandre
    Kramer, Arjen
    van Rosmalen, Martijn
    Mortensen, Franziska
    Geuijen, Cecile
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer
    de Gorter, David J.
    O'Connor, Marie
    Deshiere, Alexandre
    van Rosmalen, Martijn
    Fatrai, Szabolcs
    van Bueren, Jeroen Lammerts
    Geuijen, Cecile A.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study
    Ou, S. H.
    Garcia, V. Moreno
    Bazo, I. Gil
    Prenen, H.
    Moreno, I.
    Johnson, M.
    Alvarez, E. Castanon
    Nagasaka, M.
    Adeyemi, S.
    Barasa, B.
    Bol, K.
    Doze, P.
    Engbers, A.
    Joe, A. K.
    Stalbovskaya, V.
    Laus, G.
    Call, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S122 - S122
  • [8] The bispecific antibody MCLA-129 impairs NSCLC tumor growth by targeting EGFR and c-MET, inhibiting ligand-induced signaling and promoting ADCC and ADCP.
    de Gorter, David J.
    Deshiere, Alexandre
    van Rosmalen, Martijn
    Wohn, Christian
    Eppink, Berina
    Gallenne, Tristan
    Klooster, Rinse
    Mao, Li
    Xu, Wenxin
    Deng, Liang
    Shu, Qingyu
    Liu, Wei
    de Kruif, John
    Di Matteo, Mario
    Mazzone, Massimiliano
    Throsby, Mark
    Geuijen, Cecile A.
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
    Cohen, Ezra E.
    Fayette, Jerome
    Daste, Amaury
    Even, Caroline
    Le Tourneau, Christophe
    Brana, Irene
    Saada, Esma
    Fontana, Elisa
    Iglesias, Lara
    Kato, Shumei
    Garcia-Carbonero, Rocio
    Tabernero, Josep
    Argiles, Guillem
    Magin, Marina
    Shen, Yu-Ming
    de Leeuw, Renee
    Bekradda, Mohamed
    Pennella, Eduardo
    Wasserman, Ernesto
    Stalbovskaya, Viktoriya
    van Bueren, Jeroen Lammerts
    Jain, Lokesh
    Joe, Andrew
    CANCER RESEARCH, 2023, 83 (08)
  • [10] Growth-factors system in anti-EGFR monoclonal antibody therapy in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
    Vladimirova, Liubov Yu
    Frantsiyants, Elena Mikhaylovna
    Engibaryan, Marina
    Agieva, Aza
    Cheryarina, Natalia D.
    Popova, Irina L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345